Reduction Of Blood Amyloid-Beta Oligomers In Alzheimer'S Disease Transgenic Mice By C-Abl Kinase Inhibition
JOURNAL OF ALZHEIMERS DISEASE(2016)
摘要
One of the pathological hallmarks of Alzheimer's disease (AD) is the presence of amyloid plaques, which are deposits of misfolded and aggregated amyloid-beta peptide (A beta). The role of the c-Abl tyrosine kinase in A beta-mediated neurodegeneration has been previously reported. Here, we investigated the therapeutic potential of inhibiting c-Abl using imatinib. We developed a novel method, based on a technique used to detect prions (PMCA), to measure minute amounts of misfolded-A beta in the blood of AD transgenic mice. We found that imatinib reduces A beta-oligomers in plasma, which correlates with a reduction of AD brain features such as plaques and oligomers accumulation, neuroinflammation, and cognitive deficits. Cells exposed to imatinib and c-Abl KO mice display decreased levels of beta-CTF fragments, suggesting that an altered processing of the amyloid-beta protein precursor is the most probable mechanism behind imatinib effects. Our findings support the role of c-Abl in A beta accumulation and AD, and propose AD-PMCA as a new tool to evaluate AD progression and screening for drug candidates.
更多查看译文
关键词
Alzheimer's disease,amyloid-beta peptide,amyloid-beta protein precursor,c-Abl tyrosine kinase,imatinib,oligomers,PMCA
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要